MI8.{1-2,4} | Genitourinary & Sexually Transmitted Infections — Case Study

CLINICAL SCENARIO

Mrs. Kavitha Rajan, a 34-year-old primary school teacher from Madurai, presents to the outpatient department with her fourth episode of dysuria, increased frequency, and cloudy urine in the past 12 months. Each prior episode was treated with a 3-day course of trimethoprim-sulfamethoxazole, with initial symptom relief. Her last culture, taken 3 months ago, grew E. coli sensitive to nitrofurantoin and co-trimoxazole. Today's midstream urine culture has been sent. She has no fever, no flank pain, no haematuria. She is married, not pregnant, does not use any contraceptives, and has no comorbidities. She is frustrated: 'Doctor, why does this keep happening to me?'

Your task is to write a structured clinical analysis addressing the microbiological and clinical dimensions of recurrent UTI, tailored to this patient.

Section 1: Definition and Classification

How is recurrent UTI defined? Is Mrs. Kavitha experiencing relapse (same organism, same serotype) or re-infection (different organisms or serotypes)? What clinical and microbiological clues help distinguish the two?

Guidance: Recurrent UTI = ≥2 UTIs in 6 months or ≥3 in 12 months. Re-infection (different organism, or different serotype of E. coli) is more common in women; relapse (same organism within 2 weeks of completing treatment) suggests upper tract focus or resistant organism. Culture comparison across episodes is the key distinguishing tool.

Section 2: Host and Behavioural Risk Factors

List anatomical, physiological, and behavioural factors that predispose this particular patient. Which factors are specific to women? Which are specific to her stage of life (pre-menopausal, sexually active)?

Guidance: Short female urethra, proximity of urethra to vagina/rectum, sexual activity (increasing fecal flora contact), no post-coital voiding, delayed micturition, inadequate hydration, incomplete bladder emptying, lack of oestrogen-driven lactobacillus flora (post-menopause is not applicable here but worth noting). Genetic factors: P blood group antigen expression on urothelium, lack of urinary IgA secretion.

Section 3: Laboratory Investigation

What specimen type is ideal for Mrs. Kavitha? How should she collect it? What colony count is significant in a symptomatic woman? What if she has already started antibiotics when the sample is collected?

Guidance: Midstream clean-catch urine (MCCSU). ≥10⁵ CFU/mL is traditional significant bacteriuria; ≥10³ CFU/mL is accepted in symptomatic women with pyuria. If antibiotics have been started, culture sensitivity falls dramatically — ideally collect before first dose. Suprapubic aspirate (any count significant) is reserved for ambiguous cases. Rapid tests: urine dipstick (nitrite + leucocyte esterase). Microscopy: >10 WBC/hpf = pyuria.

Section 4: Antimicrobial Stewardship

Why might co-trimoxazole no longer be appropriate for Mrs. Kavitha? What does previous culture sensitivity mean for today's episode? How should you decide on empiric versus targeted therapy?

Guidance: Repeated co-trimoxazole use selects for resistant E. coli (TMP resistance prevalence >20% in many Indian settings). Local antibiogram should guide empiric therapy. Her previous sensitivity does not guarantee current sensitivity. Nitrofurantoin remains effective for lower UTI (urinary concentration), but NOT for pyelonephritis. Fosfomycin 3 g single dose is a resistance-sparing alternative. Fluoroquinolones should be reserved — quinolone resistance in uropathogens is rising.

Section 5: Non-Antibiotic Prevention

Suggest at least three evidence-based non-antibiotic strategies to reduce recurrence frequency. Briefly explain the mechanism for each.

Guidance: 1. Behavioural: increased fluid intake (dilutes uropathogens, increases voiding frequency), post-coital voiding (flushes perineal bacteria). 2. Cranberry products (proanthocyanidins inhibit P-fimbriae adhesion to urothelial cells — some RCT evidence, though modest). 3. Topical vaginal oestrogen (post-menopausal patients only — restores lactobacillus flora). 4. D-mannose (binds type-1 fimbriae, blocks E. coli adhesion — emerging evidence). 5. Low-dose antibiotic prophylaxis or post-coital prophylaxis is a pharmacological option, distinct from treatment.

Section 6: Indications for Further Investigation

When should a woman with recurrent UTI be referred for urological investigation or imaging? What findings would prompt this in Mrs. Kavitha?

Guidance: Indications: UTI with obstruction (hydronephrosis, structural anomaly), relapse with the same resistant organism, UTI with haematuria, recurrent pyelonephritis, failure to respond to appropriate antibiotics, stone disease, suspected renal TB, or urodynamic dysfunction. For uncomplicated recurrent lower UTI in a premenopausal woman without the above, routine imaging is NOT indicated. If haematuria persists after UTI resolution, cystoscopy is warranted to exclude bladder lesion.

PEER REVIEW

Review your peer's assignment against each rubric criterion. For each criterion, comment on: (1) accuracy of the microbiology or clinical content, (2) depth of reasoning, and (3) one specific improvement suggestion. Maintain a respectful and constructive tone. Your peer review must be at least 150 words and address ALL six criteria.